A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates
暂无分享,去创建一个
[1] N. Lemoine,et al. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. , 1992, Oncogene.
[2] Gary H Lyman,et al. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] J. Barreto,et al. Antineoplastic Agents and the Associated Myelosuppressive Effects , 2014, Journal of pharmacy practice.
[4] H. Erickson,et al. ADME of Antibody–Maytansinoid Conjugates , 2012, The AAPS Journal.
[5] B. Nieswandt,et al. Expression and Function of the Mouse Collagen Receptor Glycoprotein VI Is Strictly Dependent on Its Association with the FcRγ Chain* , 2000, The Journal of Biological Chemistry.
[6] R. Advani,et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Miyazaki,et al. Multilineage hematopoietic recovery by a single injection of pegylated recombinant human megakaryocyte growth and development factor in myelosuppressed mice. , 1998, Blood.
[8] Patricia A Corrigan,et al. Ado-trastuzumab Emtansine , 2014, The Annals of pharmacotherapy.
[9] Suzanne F. Jones,et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Howard L McLeod,et al. A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. , 2003, Journal of applied physiology.
[11] J. W. Booth,et al. Divergent Intracellular Sorting of FcγRIIA and FcγRIIB2* , 2010, The Journal of Biological Chemistry.
[12] Scott E Smith,et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Friberg,et al. A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody–Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer , 2014, The AAPS Journal.
[14] U. Jäger,et al. Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience. , 2012, Blood.
[15] J. Borghans,et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. , 2010, Blood.
[16] M. Sliwkowski,et al. Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer , 2011, Clinical Cancer Research.
[17] V. Roy,et al. Thrombocytopenia in adults: A practical approach to evaluation and management. , 2006, Southern medical journal.
[18] Yan Chen,et al. Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate. , 2014, Bioconjugate chemistry.
[19] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] P. Senter,et al. Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates , 2014, Nature Biotechnology.
[21] Michele Signore,et al. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor. , 2007, Cancer research.
[22] C. Cordon-Cardo,et al. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. , 1990, Oncogene.
[23] John P Leonard,et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.
[24] R. Blum,et al. Maytansine: a phase I study of an ansa macrolide with antitumor activity. , 1978, Cancer treatment reports.
[25] A. Tolcher,et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Chari. Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.
[27] A. Wahl,et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] S. Rafii,et al. Tie2 activation contributes to hemangiogenic regeneration after myelosuppression. , 2005, Blood.
[29] Paul Polakis,et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.
[30] J. Harrold,et al. Semi‐mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer , 2012, Clinical pharmacology and therapeutics.
[31] Heather Donaghy,et al. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates , 2016, mAbs.
[32] B. Nieswandt,et al. Expression and function of the mouse collagen receptor glycoprotein VI is strictly dependent on its association with the FcRgamma chain. , 2000, The Journal of biological chemistry.
[33] M. Sliwkowski,et al. Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1) , 2014, Clinical Cancer Research.
[34] M. Sliwkowski,et al. Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[35] M. Sliwkowski,et al. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. , 2011, Clinical breast cancer.
[36] B. Tomczuk,et al. Current ADC Linker Chemistry , 2015, Pharmaceutical Research.
[37] B. Curtis. Drug-induced immune neutropenia/ agranulocytosis , 2014, Immunohematology.
[38] B. Gunter,et al. The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates , 2012, Molecular Cancer Therapeutics.
[39] Damon L. Meyer,et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.
[40] H. Rugo,et al. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer , 2012, Cancer Chemotherapy and Pharmacology.
[41] R. Meyboom,et al. Drug-Induced Immune Thrombocytopenia , 2004, Drug safety.
[42] Andrew C. Hooker,et al. Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models , 2011, The AAPS Journal.
[43] M. Turner,et al. The Fc receptor γ‐chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen , 1997, The EMBO journal.
[44] J. Italiano,et al. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. , 2012, Blood.
[45] R. Lutz,et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. , 2006, Cancer research.
[46] D. Benjamin,et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate , 2010, Clinical Cancer Research.
[47] J. Doroshow,et al. The promise of antibody-drug conjugates. , 2012, The New England journal of medicine.
[48] S. Owen,et al. Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry , 2015, The AAPS Journal.
[49] A. Scott,et al. Antibody–Drug Conjugates for Cancer Therapy , 2016, Biomedicines.
[50] A. Tolcher,et al. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study , 2008, Cancer Chemotherapy and Pharmacology.
[51] H. Rugo,et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] Dhaval K. Shah,et al. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[53] P. Sullivan,et al. Successful determination of platelet lifespan in C3H mice by in vivo biotinylation. , 1996, Laboratory animal science.
[54] L. Parker,et al. A therapeutic trial of maytansine. , 1978, Cancer clinical trials.
[55] E. Wright,et al. Haemopoietic stem cells: their heterogeneity and regulation , 1997, International journal of experimental pathology.
[56] Qiuyang Zhang,et al. Monomethyl Auristatin E Phosphate Inhibits Human Prostate Cancer Growth , 2016, The Prostate.
[57] R. Advani,et al. A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies , 2011, Clinical Cancer Research.
[58] H. Scher,et al. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. , 2008, Journal of Clinical Oncology.
[59] Uma Yasothan,et al. Brentuximab vedotin , 2012, Nature Reviews Drug Discovery.
[60] Damon L. Meyer,et al. Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.
[61] Aman P. Singh,et al. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1) , 2016, The AAPS Journal.